ACB · Aurora Cannabis Inc. · Stock research

Current Thesis

The frame flipped on 2026-08-11. Aurora had been trading as sentiment beta to a US reschedule whose economics never reached a Canadian LP; it is now a take-over target with a named strategic bidder and published terms. Curaleaf announced its intention to bid for all Aurora common shares at an implied US$4.00 — 0.3463 Curaleaf subordinate voting shares plus US$0.75 cash — a 45% premium to Aurora's US$2.75 30-day VWAP, with the implied value capped at US$5.00. Aurora's board responded the same session by forming a special committee of independent directors and noting publicly that the US$5.00 cap sits below where its shares traded on 2025-12-18. Two trading halts hit the tape that day.

Bullish and bearish views on Aurora Cannabis Inc.

The model's bull view on Aurora Cannabis Inc. (ACB), in brief: Public terms from a named strategic bidder, 2026-08-11. The bear view: No bid exists yet. The 2026-08-11 Curaleaf release states no formal take-over bid has been commenced and there is no assurance the proposed offer is ultimately made. The premium in the tape is priced off a stated intention. Mostly acquirer paper, and capped. US$0.75 per share is… Both cases follow in full.

Bull Case

• Public terms from a named strategic bidder, 2026-08-11. 0.3463 Curaleaf shares + US$0.75 cash, implied US$4.00, a 45% premium to the US$2.75 30-day VWAP; MJBizDaily and Investing News put the implied transaction value at roughly US$272M.
• The offer is thin against the balance sheet. Aurora reported FY2026 on 2026-06-11 as debt-free with $165M cash. An implied ~US$272M equity value against that cash position is the arithmetic behind the board's inadequacy framing, and it makes a raised offer or a competing bidder a live possibility rather than a hopeful one.
• A two-month private negotiation preceded the public move. Curaleaf's letters are dated 2026-06-23 and 2026-07-07 (only the July letter carried financial terms, since modified); Aurora disputed the "refused to engage" characterisation, citing lead-independent-director contact with Curaleaf CEO Boris Jordan as recently as 2026-07-24.
• Bottom line beat on the 2026-08-05 print. Q1 FY2027 EPS -$0.05 versus -$0.13 consensus.
• The asset Curaleaf says it wants is compounding. FY2026 (reported 2026-06-11): record global medical net revenue $289M, +18% YoY; adjusted EBITDA $54M, +32%; international medical $177M, with 55% of revenue outside Canada.

Bear Case

• No bid exists yet. The 2026-08-11 Curaleaf release states no formal take-over bid has been commenced and there is no assurance the proposed offer is ultimately made. The premium in the tape is priced off a stated intention.
• Mostly acquirer paper, and capped. US$0.75 per share is cash; the balance is Curaleaf subordinate voting stock, which trades on the TSX and OTCQX rather than a US national exchange because of Curaleaf's US plant-touching operations. The implied US$4.00 floats with Curaleaf's share price and the consideration value is capped at US$5.00 — Aurora's own 2026-08-11 statement flags that cap as below its 2025-12-18 trading level.
• Fundamentals kept softening into the bid. Q1 FY2027 (2026-08-05) revenue $48.798M missed the $50.510M consensus and stepped down from $61.842M in Q4 FY2026. FY2027 is guided as a transitional year: total net revenue back toward FY2025 levels, adjusted gross margin easing to the mid-to-high 50s from 64%, on a ~30% Canadian medical reimbursement cut effective 2026-04-01.
• The policy leg stays dormant. The DEA Schedule-III hearing closed ~2026-07-15 with no ALJ recommendation timeline, and the 2026-04-28 downschedule order covers state-medical and FDA-approved products — US-operator economics (280E relief), which a Canadian LP with no US THC operations does not collect.

Setup & Price Structure

• 2026-08-14 close $3.68, 40.9% below the $6.23 52-week high; three-month return 10.8%, effectively all of it earned in one session.
• RSI(14) 79.7 at that close. The move is one event gap, not accumulation across weeks.
• Two halts on 2026-08-11 — a news-pending halt at 11:57 a.m. ET and a resumption notice at 4:15 p.m. ET. Stocktwits characterised the session as the biggest single-day rally in nearly 11 months.
• that is the zone the tape reverts toward if the process lapses.
• $3.68 trades below the US$4.00 implied consideration. The discount is what the market charges for an uncommenced, mostly-stock, value-capped hostile offer whose target board has already signalled the price is inadequate.
• The narrative is accelerating, dated 2026-08-11 — fresh headlines, two halts, expanding participation off a base near the $2.75 VWAP, and a special committee that has not yet reported. Nothing in the flow yet resembles a crowded, late-cycle bid; equally, the entire narrative is four trading days old.

Catalyst Calendar (next 30 days)

• Undated, expected within weeks (est.) — Curaleaf mailing a formal take-over bid circular. Under Canada's NI 62-104 a commenced bid must remain open for a minimum 105-day deposit period unless the target board reduces it to no fewer than 35 days.
• Within 15 days of any formal commencement (NI 62-104) — Aurora directors' circular carrying the special committee's recommendation, and any shareholder rights plan adopted alongside it.
• ~2026-11-05 (est.) — Q2 FY2027 print, the next fundamental checkpoint on whether revenue stabilises above the $48.798M Q1 level.

Elapsed catalysts

• 2026-08-17 — DEA Schedule-III post-hearing brief deadline. Sector sentiment only; an ALJ recommendation and administrator decision remain undated, so the date passing without a schedule leaves the policy leg where it was. (passed 9d ago)

What Would Change Our Mind

• The process dying quietly is the main break: no circular mailed, the stated intention lapsing, and the premium having nothing to stand on. The gradeable version is a weekly close below $3.05, which gives back the bulk of the 2026-08-11 gap and reads as the market pricing a failed bid back toward the US$2.75 pre-announcement VWAP.
• On the constructive side, a formal circular at terms above US$4.00, a competing bidder, or a special-committee recommendation of a negotiated deal converts a capped ceiling into a floor.
• A Q2 FY2027 revenue print below $48.798M strengthens Curaleaf's argument that US$4.00 is full, and weakens any case for a raise.
• If the stock chops between roughly $3.60 and $4.00 for several weeks with no circular and coverage thins, the narrative label moves toward maturing and the event premium bleeds without a price break.

Correlation Notes

• Implied deal value is now mechanically linked to Curaleaf: at 0.3463 Curaleaf shares per Aurora share, a Curaleaf drawdown lowers the consideration, while a Curaleaf rally is truncated by the US$5.00 cap.
• Residual beta to the US reschedule tape (MSOS, GTBIF, CURLF, TCNNF) persists, but the 280E economics accrue to US operators.
• Canadian LP peers (TLRY, CGC, OGI) carry read-across risk from a first cross-border consolidation attempt at this scale.